Tadalafil, a phosphodiesterase type 5 inhibitor, restores urethra and detrusor function in the initial phase of diabetes in rats.
Animals
Carbachol
/ pharmacology
Diabetes Mellitus, Experimental
/ complications
Electric Stimulation
Female
Muscle Contraction
/ drug effects
Muscle, Smooth
/ drug effects
Phosphodiesterase 5 Inhibitors
/ therapeutic use
Rats
Rats, Sprague-Dawley
Tadalafil
/ therapeutic use
Urethra
/ drug effects
Urinary Bladder
/ drug effects
detrusor
diabetes
phosphodiesterase 5
rat
tadalafil
urethra
Journal
Lower urinary tract symptoms
ISSN: 1757-5672
Titre abrégé: Low Urin Tract Symptoms
Pays: Australia
ID NLM: 101506777
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
25
01
2019
revised:
02
05
2019
accepted:
11
05
2019
pubmed:
18
6
2019
medline:
13
2
2020
entrez:
18
6
2019
Statut:
ppublish
Résumé
This study investigated the effects of tadalafil on the urethra and detrusor in the initial phase of diabetes in rats. Thirty-six female Sprague-Dawley rats were assigned to a non-diabetes (ND), diabetes (D), or tadalafil-treated diabetes (DT) group (n = 12 per group), with the DT group receiving oral tadalafil (2 mg/kg/d) for 7 days before the experiments. Seven weeks after diabetes induction (by a single intraperitoneal injection of streptozotocin), urethral and intravesical pressure were simultaneously recorded in vivo, whereas responses of detrusor strips to potassium chloride (30 mM), electrical field stimulation (EFS) and carbachol were measured in vitro. The intravesical pressure at which the urethra started to relax was significantly lower in the DT than D group (mean [± s.d.] 18.9 ± 2.9 vs 29.1 ± 6.6 cm H Tadalafil restored urethral relaxation function and detrusor responses to EFS and carbachol during the initial phase of diabetes.
Substances chimiques
Phosphodiesterase 5 Inhibitors
0
Tadalafil
742SXX0ICT
Carbachol
8Y164V895Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
241-247Informations de copyright
© 2019 John Wiley & Sons Australia, Ltd.
Références
Yamaguchi O, Nomiya M, Andersson KE. Functional consequences of chronic bladder ischemia. Neurourol Urodyn. 2014;33:54-58.
Goligorsky MS. Vascular endothelium in diabetes. Am J Physiol Renal Physiol. 2017;312:F266-F275.
Daneshgari F, Leiter EH, Liu G, Reeder J. Animal models of diabetic uropathy. J Urol. 2009;182:S8-S13.
Torimoto K, Fraser MO, Hirao Y, De Groat WC, Chancellor MB, Yoshimura N. Urethral dysfunction in diabetic rats. J Urol. 2004;171:1959-1964.
Takeda M, Yokoyama O, Lee SW, Murakami M, Morisaki Y, Viktrup L. Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea. Int J Urol. 2014;21:670-675.
Guo YL, Zhu JC, Pan TM, et al. Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in South-east Asian men. Int J Urol. 2006;13:721-727.
Zhao Y, Vanhoutte PM, Leung SW. Vascular nitric oxide: beyond eNOS. J Pharmacol Sci. 2015;129:83-94.
Andersson KE, de Groat WC, McVary KT, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011;30:292-301.
Gotoh D, Torimoto K, Tatsumi Y, et al. Tadalafil, a phosphodiesterase type 5 inhibitor, improves bladder blood supply and restores the initial phase of lower urinary tract dysfunction in diabetic rats. NeurourolUrodyn. 2018;37:666-672.
Kawai Y, Oka M, Yoshinaga R, Fuchikami C, Oyama T. Effects of the phosphodiesterase 5 inhibitor tadalafil on bladder function in a rat model of partial bladder outlet obstruction. NeurourolUrodyn. 2016;35:444-449.
Sawamura F, Kato M, Fujita K, Nakazawa T, Beardsworth A. Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats. J Pharmacol Sci. 2009;111:235-243.
Hill SR, Fayyad AM, Jones GR. Diabetes mellitus and female lower urinary tract symptoms: a review. Neurourol Urodyn. 2008;27:362-367.
Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015;116:1509-1526.
Andersson KE, Garcia Pascual A, Persson K, Forman A, Tottrup A. Electrically-induced, nerve-mediated relaxation of rabbit urethra involves nitric oxide. J Urol. 1992;147:253-259.
Masuda H, Tsujii T, Okuno T, Kihara K, Goto M, Azuma H. Involvement of accumulated endogenous NOS inhibitors and decreased NOS activity in the impaired neurogenic relaxation of the rabbit proximal urethra with ischaemia. Br J Pharmacol. 2001;133:97-106.
Kadekawa K, Majima T, Kawamorita N, et al. Effects of an alpha1A/D-adrenoceptor antagonist, naftopidil, and a phosphodiesterase type 5 inhibitor, tadalafil, on urinary bladder remodeling in rats with spinal cord injury. Neurourol Urodyn. 2017;36:1488-1495.
Maggi CA, Santicioli P, Meli A. The nonstop transvesical cystometrogram in urethane-anesthetized rats: a simple procedure for quantitative studies on the various phases of urinary bladder voiding cycle. J Pharmacol Methods. 1986;15:157-167.
Nishizawa O, Satoh S, Harada T, et al. Role of the pudendal nerves on the dynamics of micturition in the dog evaluated by pressure flow EMG and pressure flow plot studies. J Urol. 1984;132:1036-1039.
Jubelin B, Galeano C, Ladouceur D, Lemaire S, Elhilali MM. Effect of enkephalin on the micturition cycle of the cat. Life Sci. 1984;34:2015-2027.
Maggi CA, Giuliani S, Santicioli P, Meli A. Analysis of factors involved in determining urinary bladder voiding cycle in urethane-anesthetized rats. Am J Physiol. 1986;251:R250-R257.
Yoshizawa T, Hayashi Y, Yoshida A, et al. Concomitant alteration in number and affinity of P2X and muscarinic receptors are associated with bladder dysfunction in early stage of diabetic rats. Int Urol Nephrol. 2018;50:451-458.
Chancellor MB. The overactive bladder progression to underactive bladder hypothesis. Int Urol Nephrol. 2014;46(suppl 1):S23-S27.
Munoz A, Smith CP, Boone TB, Somogyi GT. Overactive and underactive bladder dysfunction is reflected by alterations in urothelial ATP and NO release. Neurochem Int. 2011;58:295-300.